Orphazyme A/S
ORPH
ORPH was delisted on the 30th of March, 2022.
20 hedge funds and large institutions have $5.77M invested in Orphazyme A/S in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 7 closing their positions.
164% more capital inflows, than outflows
Capital inflows: $6.26M | Capital outflows: $2.38M
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
122% more funds holding
Funds holding: 9 → 20 (+11)
1.41% more ownership
Funds ownership: 0.83% → 2.24% (+1.4%)
16% less call options, than puts
Call options by funds: $5.87M | Put options by funds: $7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.65M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.24M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$864K |
| 4 |
BAM
Blueshift Asset Management
Red Bank,
New Jersey
|
+$574K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$550K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.12M |
| 2 |
Millennium Management
New York
|
-$1.02M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$169K |
| 4 |
PHK
Point72 Hong Kong
Hong Kong
|
-$40K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$19K |
ORPH Hedge Fund Activity: Q2 2021 in Review
20 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Orphazyme A/S (ORPH) for Q2 2021, worth a combined $5.77M — up 138% from $2.42M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ORPH positions and 7 closed out — a net gain of 11 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $1.65M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.12M sold.
- 20 institutional investors held Orphazyme A/S (ORPH) as of Q2 2021, up from 9 in Q1 2021.
- Funds reported $5.77M of Orphazyme A/S stock for Q2 2021, up 138% quarter-over-quarter.
- 18 funds opened new Orphazyme A/S positions in Q2 2021 and 7 closed out, a net change of +11 holders.
- The largest Orphazyme A/S buyer in Q2 2021 was Jane Street, an estimated $1.65M added.
- The largest Orphazyme A/S seller in Q2 2021 was Point72 Asset Management, an estimated $1.12M sold.
Based on aggregated 13F filings for Q2 2021.